Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.

Tecentriq (atezolizumab) - Roche

prexasertib (ACR-368) - Acrivon Therap

http://www.ncbi.nlm.nih.gov/pubmed/41196428

Feiquan Ying; Jing Cai; Lin Huang; Lin Liu; Mengna Zhu; Mengqing Chen; Si Sun; Wenhan Li; Yiping Wen

Nov 6, 2025